2 completed, 2 unknown, 1 not yet recruiting. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Meningococcal Meningitis: new trials by email Literature Review of Meningococcal Meningitis trials Research Report on Meningococcal Meningitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine - Meningococcal Meningitis | Phase 1 | Not yet recruiting | Sinovac Life Sciences Co., Ltd. | 150 | 2026-01-21 | 2026-01-28 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free), Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant) - Meningitis, Meningococcal Meningitis | Phase 1 / Phase 2 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 360 | 2016-08-01 | 2016-09-29 |
| A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine freeze-dried group ACYW135 MCV - Meningococcal Meningitis | Phase 1 | Unknown | Lanzhou Institute of Biological Products Co., Ltd | 200 | 2015-06-01 | 2015-06-25 |
| Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis meningococcal meningitis conjugate vaccine, quadrivalent - Meningococcal Meningitis, Meningococcal Infections | Phase 1 | Completed | JN-International Medical Corporation | 60 | 2011-11-01 | 2013-01-14 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate - Meningococcal Infections, Meningococcal Meningitis | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 216 | 2007-10-01 | 2013-09-20 |
Meningitis, Meningococcal (5) · Meningococcal Infections (3) · Meningitis (2) · Central Nervous System Infections (1)
Bacterial Infections (5) · Bacterial Infections and Mycoses (5) · Central Nervous System Bacterial Infections (5) · Central Nervous System Diseases (5) · Gram-Negative Bacterial Infections (5) · Infections (5) · Meningitis, Bacterial (5) · Neisseriaceae Infections (5) · Nervous System Diseases (5) · Neuroinflammatory Diseases (5) · Central Nervous System Infections (4) · Meningitis (3) · Meningococcal Infections (2)
CRM197 (non-toxic variant of diphtheria toxin) (1) · HibTITER protein, Haemophilus influenzae (1) · Meningococcal Vaccines (1)
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · JN-International Medical Corporation (1) · Lanzhou Institute of Biological Products Co., Ltd (1) · Sanofi Pasteur, a Sanofi Company (1) · Sinovac Life Sciences Co., Ltd. (1)
China (2) · United States (2)